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AbstrACt
Introduction Childhood infections, particularly those 
caused by helminths are considered to be important 
environmental exposures influencing the development 
of allergic diseases. However, epidemiological studies 
focusing on the relationship between helminth infections 
and risk of allergic diseases, performed worldwide, show 
inconsistent findings. Previous systematic reviews of 
observational studies published 10 or more years ago 
showed conflicting findings for effects of helminths 
on allergic diseases. Over the past 10 years there has 
been growing literature addressing this research area 
and these need to be considered in order to appreciate 
the most contemporary evidence. The objective of the 
current systematic review will be to provide an up- to- date 
synthesis of findings of observational studies investigating 
the influence of helminth infections on atopy, and allergic 
diseases.
Methods and analysis This systematic review protocol 
was registered at PROSPERO. We will search Cochrane 
Library, MEDLINE, EMBASE, CINAHL, AMED, ISI Web of 
Science, WHO Global Health Library, Scielo, IndMed, 
PakMediNet, KoreaMed, Ichushi for published studies 
from 1970 to January 2020. Bibliographies of all eligible 
studies will be reviewed to identify additional studies. 
Unpublished and ongoing research will also be searched in 
key databases. There will be no language or geographical 
restrictions regarding publications. Critical Appraisal 
Skills Programme quality assessment tool will be used 
to appraise methodological quality of included studies. A 
descriptive summary with data tables will be constructed, 
and if adequate, meta- analysis using random- effects 
will be performed. The Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses checklist will be 
followed for reporting of the systematic review.
Ethics and dissemination Since this systematic review 
will be only based on published and retrievable literature, 
no ethics approval will be sought. The multidisciplinary 
team performing this systematic review will participate 
in relevant dissemination activities. Findings will 
be presented at scientific meetings and publish the 
systematic review in international, peer- reviewed, open- 
access journals.
PrOsPErO registration number CRD42020167249.
IntrOduCtIOn
Intestinal parasites include a large group of 
micro- organisms of which protozoans and 
helminths are of most relevance to human 
health.1 Most prevalent are the nematode 
helminth group, including Ascaris lumbri-
coides, Trichuris trichiura and hookworms 
(Necator americanus and Ancylostoma duode-
nale).2 Prevalence varies by geographic 
region and is greatest in endemic areas of 
sub- Saharan Africa, Latin America, China 
and Eastern Asia, where such infections are 
linked to poverty and poor sanitation.1 3–5
Allergic diseases such as asthma and 
rhinitis, and eczema affect millions world-
wide.6–8 Among environmental exposures 
considered to influence the development 
of allergic diseases are childhood infections 
including helminths. Helminths are capable 
strengths and limitations of this study
 ► This is the first systematic review to address the 
relationship between a wide variety of helminth 
infections and atopy and the most frequent aller-
gic diseases in children (ie, asthma, rhinitis and 
eczema).
 ► A thorough search strategy using leading databases 
in medicine and public health will ensure that the 
relevant papers on the topic will be identified.
 ► This protocol followed the Preferred Reporting Items 
for Systematic Review and Meta- Analysis Protocols 
guidelines.
 ► With no restriction by language or geography, this 
systematic review will provide a comprehensive and 
global picture on the topic and enables investiga-
tions into any regional differences.
 ► Different epidemiological definitions of allergic dis-
eases, as well as the consideration of a wide variety 
of helminth parasite species for which numbers of 
eligible studies may be limited, may affect the va-
lidity of any subgroup meta- analyses by parasite 
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of producing immunological mediators that modulate 
host immune responses, particularly allergic inflam-
mation.9 10 However, results of epidemiological studies 
addressing the relationship between helminth infections 
and risk of allergic diseases, done in almost all geographic 
regions of the world, show inconsistent findings.11–18
There are only two previous systematic reviews of obser-
vational studies investigating the relationship between 
helminth infections and allergy: (1) a systematic review 
included 30 studies published up to 2006 in a meta- 
analysis of the relationship between helminths and 
asthma symptoms and showed overall no association but 
parasite- specific effects were observed—hookworm was 
associated with a reduced while A. lumbricoides was associ-
ated with an increased risk of symptoms19; (2) a systematic 
review of 21 observational studies published up to 2009, 
studied the relationship between helminths and allergen 
skin prick test (SPT) reactivity and showed an inverse 
association between helminths and SPT.20 Three other 
more recent systematic reviews have studied the relation-
ship between Toxocara spp seroprevalence and allergy: 
(1) a meta- analysis from 2013 of 10 studies addressing 
the association between Toxocara spp and asthma showed 
an increased risk21; (2) a systematic review from 2017 
concluded that children infected with Toxocara spp were 
more likely to have asthma22 and (3) a study from 2018 
showed that Toxocara spp was associated with an increased 
risk of urticaria but not with atopy or eczema.23
Existing systematic reviews and meta- analyses investi-
gating the role of various helminth intestinal parasites in 
atopy or allergic diseases are 10 or more years old and 
considered few allergic outcomes (eg, asthma or atopy). 
As detailed above, more recent systematic reviews have 
focused only on Toxocara spp infections. Given these 
important gaps and diverging results in the literature, 
the aims of the current systematic review are to identify, 
critically appraise and synthesise the evidence from obser-
vational epidemiological studies investigating the influ-
ence of various species and parasite burdens of helminth 
infections on the: (1) risk of developing asthma, rhinitis, 
eczema and/or atopy and (2) the expression of clinical 
outcomes and disease severity in patients with already 
established allergic diseases. Because of the recent system-
atic reviews addressing toxocariasis, Toxocara spp will not 
be considered here.
MEthOds And AnAlysIs
This study has been registered with the International 
prospective register of systematic reviews (PROSPERO). 
The review will be reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guidelines for systematic 
reviews and MOOSE (Meta- analysis of Observational 
Studies in Epidemiology) guidelines for meta- analysis of 
observational epidemiological studies.24 25 Any modifica-
tions in the protocol during the systematic review will be 
reported.
search strategy
We have developed a comprehensive search strategy for 
retrieving published and unpublished studies on the 
topic (online supplementary appendix 1). We will search 
the Cochrane Library (Cochrane Database of System-
atic Reviews, Cochrane Central Register of Controlled 
Trials (CENTRAL), Cochrane Methodology Register), 
MEDLINE, EMBASE, CINAHL, AMED, ISI Web of Science 
(Science and Social Science Index), WHO Global Health 
Library (which encompasses African Index Medicus, 
Index Medicus for the Eastern Mediterranean Region, 
Index Medicus for the South- East Asia, Latin America 
and the Caribbean Literature on Health Sciences and 
Western Pacific Region Index Medicus), Scielo, IndMed, 
PakMediNet, KoreaMed and Ichushi (updated by Japan 
Medical Abstracts Society). Search dates will be from 1970 
(or from the inception of a database if this occurs later 
than 1970) to present. The bibliographies of all eligible 
studies will be reviewed to identify additional possible 
studies. We will identify unpublished and ongoing work 
and research in progress by searching key Internet- based 
relevant databases ( www. clinicaltrials. gov; www. clin ical 
tria lsre gister. eu; www. controlledtrials. com; www. anzctr. 
org. au). In addition, we will contact authors who have 
published in this field to ask for potentially additional 
papers. No language restrictions will be imposed; transla-
tions will be undertaken where necessary.
Inclusion criteria for study designs
We will include all observational and analytical epidemio-
logical studies, including cohort, case–control and cross- 
sectional studies.
We will select all the studies that include participants 
of any age, in which the relationship between helminth 
infection and respiratory allergic diseases, atopic eczema 
and/or atopy has been studied and include studies inves-
tigating any type of helminth infection, including Entero-
bius vermicularis, A. lumbricoides, T. trichiura, hookworm 
(A. duodenale and N. americanus), Strongyloides stercoralis, 
Hymenolepsis spp (H. nana and H. diminuta) and Schisto-
soma spp (S. mansoni and S. haematobium). Toxocara spp 
infections will not be considered in this review given the 
recent systematic review that considered it. Where appli-
cable, the comparator to helminth infection will be no 
infection. Some studies would have compared different 
types of helminth infections and load of infection; we will 
maintain these comparisons in the systematic review.
We will exclude discussion papers, non- research letters 
and editorials, randomised controlled trials, clinical case 
studies and case- series, and animal studies.
study selection
Papers retrieved from the databases will be exported 
to a reference management programme where further 
screening will be undertaken. Removal of duplicate 
publications will be performed, thereafter, the titles and 
abstracts of retrieved papers will be checked by two inves-
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will be retrieved and independently assessed against 
the inclusion criteria (see above) by two reviewers. The 
reviewers will decide which of the studies fit the inclusion 
criteria. Any disagreements will be resolved by discussion, 
with a third reviewer arbitrating in the circumstance of 
unresolved discrepancies.
To ensure transparency, the process of selection will be 
summarised using a PRISMA flow diagram.
data extraction and management
Data from selected articles will be transferred from their 
original presentation to a proper form made in Micro-
soft Excel software, with each study receiving a reference 
code. Each study will have its own extraction form. If 
necessary, we will collect indirect data from figures and 
charts, adapting their interpretation from two different 
authors by consensus and authors of original articles will 
also be contacted for further information and data.
For all included studies, we will be collect the following 
information: study design, number of participants and 
their characteristics (namely, wheezing due to early- life 
respiratory viral infections, early childhood respiratory 
infections, personal and family history of allergies, house-
hold smoking), country of study, year of publication, 
profiles of helminth infection (presence, load, duration 
of infection, types of parasites, monoinfection or coin-
fection, recent or ancient treatment, frequency of infec-
tion), geographical differences; estimates (HR, risk ratio, 
OR, 95% CIs, mean and SD) of the association between 
helminth infection and the study outcomes; confounding 
factors will also be analysed, if reported, namely malaria, 
tuberculosis or HIV coinfection, technical aspects of deter-
mination/operational definition of helminth infection.
Data extraction will be completed independently by 




Estimates of association between helminth infection and 
incidence of asthma (either doctor diagnosed or wheeze 
in the past 12 months—eg, ISAAC (International Study 
of Asthma and Allergies in Childhood) study definition 
or other comparable definitions), allergic rhinitis (doctor 
diagnosed or as defined in the ISAAC study or other 
comparable definitions), eczema (flexural dermatitis 
diagnosed by doctor or as defined in the ISAAC study or 
other comparable definitions) and atopy (assessed using 
allergen- specific IgE or SPTs).
Secondary outcome
Estimates of association between helminth infection and 
clinical outcomes of respiratory allergic diseases, including 
exacerbations, hospitalisations, severity according to clin-
ical/symptoms evaluation (using any type of validated 
scale or questionnaire) and health- related quality of life 
(using any type of validated scale or questionnaire).
Quality assessment
Risk of bias assessment will be independently undertaken 
by two different reviewers, using the Critical Appraisal 
Skills Programme26 quality assessment tool for the types 
of included studies. We will appraise different compo-
nents of each study, including appropriateness of study 
design, potential for selection bias, measurement of 
exposures and outcomes and generalisability of the study 
findings. For each study, the grading of each individual 
components and the global study rating will be assigned 
categories of risk of bias: low, moderate and high. The 
global grading will involve taking an average of all indi-
vidual components. Any disagreements not resolved by 
discussion will be arbitrated by a third reviewer.
Quantitative assessment
If necessary, and according to the available reported 
data on risk associations, a quantitative analysis will be 
performed to obtain effect estimations, heterogeneity 
and consistency tests. Forest plots will be used to graphi-
cally present the results of the meta- analysis. Funnel plots 
will be used to graphically assess small study effect, which 
is one type of publication bias. Heterogeneity between 
effect sizes of included studies will be assessed by visual 
inspection of forest plots and by using the χ2 test for 
heterogeneity (with a p value of <0.1) and inconsistency 
between studies will be described using the percentage of 
the variability in effect estimates that is due to heteroge-
neity rather than chance (I2). It is generally accepted that 
I2 values up to 25%, 50% and 75% represent low, medium 
and high levels of heterogeneity or inconsistency, respec-
tively,27 28 although it is now clear that this statistics is 
not an absolute measure of such heterogeneity and 
rather indicates the proportion of observed variance that 
reflects variance in true effect sizes rather than sampling 
error.29 We plan to use Mantel- Haenzsel risk ratios with 
a random- effects model and 95% CI for dichotomous 
data. Continuous outcomes (such as symptoms or quality 
of life assessments) will be analysed as standardised 
mean difference values using a random- effects model 
and 95% CI, because the included studies may report 
different measurement instruments. We also plan to 
performed sensitivity analysis of the included studies and 
their impact on meta- analysis. If results from longitudinal 
studies allow, the primary outcomes (such as risk ratios or 
HRs) will also be analysed with an adaptation form trial 
sequential analysis using O’Brien Fleming monitoring 
boundaries approach, in order to avoid false positive 
or negative results of the pooled meta- analysis, thereby 
avoiding false or negative results.30 Subgroup analysis may 
be performed according to different reported species of 
helminths or diseases, rural versus urban settings, age 
groups, geographical regions and by study design.
data synthesis
We will produce a descriptive summary table of all 
included studies in order to summarise the literature. For 








pen: first published as 10.1136/bmjopen-2020-038085 on 25 May 2020. Downloaded from 
4 Arrais M, et al. BMJ Open 2020;10:e038085. doi:10.1136/bmjopen-2020-038085
Open access 
of effect of helminth infection and the outcomes), we will 
undertake a narrative synthesis of the data in which we 
use texts to describe the overall findings from the studies, 
highlight their strengths and weaknesses and make 
textual comparisons between the studies in this category 
in the light of the study question. For studies we judge 
to be reasonably clinically and methodologically homo-
geneous (ie, have used similar methods with regards 
to subject selection and inclusion, helminth definition 
and assessment, outcome definition and assessment and 
statistical analyses), we will perform meta- analyses using 
random- effects models to estimate the combined effect 
of helminth infection on each of the study outcome. The 
meta- analysis for the association between helminth infec-
tion and each outcome will be undertaken separately. We 
will quantify the heterogeneity between studies using the 
I2 statistic, which is a measure (range 0%–100%) used to 
quantify the proportion of variance in the pooled esti-
mates attributable to differences in estimates between 
studies included in the meta- analysis.27–30 The between- 
study variance will be estimated using the Tau- squared 
(τ2) statistic derived from the DerSimonian- Laird 
approach.31 Where data are available, we will perform 
subgroup analyses according to rural versus urban 
settings, age groups, geographical regions of the world 
and by other potential characteristics, such as study 
design (cohort, case–control, cross- sectional studies). We 
will perform sensitivity analyses based on the sample size 
of included studies as well as on the basis of the risk of 
bias results in the studies in order to assess the robustness 
of our findings to different assumptions. In the case of 
sensitivity analysis on the basis of study quality, we will 
estimate the combined effect estimates from all studies 
regardless of their quality grading (low, moderate, high). 
Then we will exclude all low- quality studies, leaving the 
moderate and high- quality studies; we will then compare 
the results to the results when all studies were combined 
regardless of their quality. We will repeat the process 
by excluding the moderate quality studies, leaving only 
the high- quality studies and then we will compare the 
results to those from the previous results. We will assess 
evidence of publication bias using funnel plots and statis-
tically using Begg and Egger tests.32 33 The meta- analyses 
will be performed using Stata statistical software (release 
V.13; StataCorp LP., College Station, Texas, USA). The 
PRISMA checklist will be followed for reporting of the 
systematic review.
Ethics and data management plan
No ethical approval required because the data to be 
collected and analysed will be based only on the published 
literature and therefore cannot be linked to specific indi-
viduals. Retrieved data will be kept in a database that will 
have protected access and will only be used by the involved 
authors. However, anonymised data will be placed in an 
open repository.
Patient and public involvement
Since this will be a systematic review, there will be no 
direct patient or public involvement.
EthICs And dIssEMInAtIOn
This systematic review will allow us, for the first time, to 
synthesise the findings of observational studies addressing 
the associations between a wide variety of relevant 
helminth parasites and common allergic outcomes. The 
review will be based on publications published between 
1970 and January 2020, and will allow us to analyse 
methodological aspects of selected studies namely study 
design, regarding the questions, methods used and risk 
of selection bias.
More specifically, our review will fill in an important 
gap since previous systematic reviews are either dated 
or focused on a single helminth (eg, Toxocara). Thus, 
our study will provide relevant up- to- date information 
on current knowledge of helminth- allergy associations 
in children and adults. This will be done by accessing 
information worldwide without geographical or language 
restrictions in which; (1) various parameters related to 
helminth infection will be analysed—types of helminths, 
infection load, frequency of infections, among other; 
(2) the relationship will be analysed between helminth 
parameters and not just a single allergic disease but on 
a broader context of atopy, asthma, allergic rhinitis and 
eczema and (3) the relationship will not only be analysed 
in terms of risk of disease development but also regarding 
disease severity.
We believe our results should allow us to draw mean-
ingful conclusions about the relevance and type of effects 
involved in the relationship between helminth infections 
and atopy, asthma and allergic diseases in children and 
adults, and may have clinical and societal implications.
Our dissemination strategy will involve presentations 
at scientific meetings, as well as publication of article(s) 
in international, peer- reviewed, open- access journals. 
However, given the increasing relative percentage of chil-
dren with atopy, asthma and allergic diseases worldwide, 
particularly in certain geographical areas, the relevant 
burden of helminth infections in certain parts of the 
world, we also plan to organise meetings with general 
practitioners and other healthcare providers, as well as 
with local communities (namely in Africa) to analyse and 
discuss our findings and their potential implications.
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